Compare Global X FTSE Southeast Asia ETF (ASEA) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Smith & Nephew plc — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.65, while Smith & Nephew plc trades at $30.7 (market cap $12.69B). The key difference: Smith & Nephew plc pays a 2.55% dividend while Global X FTSE Southeast Asia ETF pays none, and Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| ASEA | SNN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $20.65 | $38.70 |
52-Week Low | $16.31 | $28.73 |
Market Cap | — | $12.69B |
Enterprise Value | — | $15.46B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
Smith & Nephew (SNN) trades at $30.70, up 0.99% with a bullish technical signal supported by moving averages. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B (2024-2025) and net income margin expanding to 10.14%. Recent developments include new medical guidance publications and robotics platform advancements, while analyst consensus remains cautious with 68% hold ratings.
SNN presents a mixed outlook with strong profitability metrics and positive cash flow trends offset by recent earnings misses and conservative analyst sentiment. Investment opportunity lies in the company's medical technology innovations and margin expansion, though risks include competitive pressures and execution challenges in meeting growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
